SCHEMBL353750

SCHEMBL353750

COC1(OC)C(NC(=O)c2cccnc2O)=CC(=O)C2OC21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.36
MEN1 O00255 6/20 0.36
RAB9A P51151 3/20 0.36
GAA P10253 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
KDM4E B2RXH2 5/20 0.35
ALDH1A1 P00352 4/20 0.35
CNR2 P34972 1/20 0.35
MAPT P10636 2/20 0.34
LMNA P02545 2/20 0.34
EGLN1 Q9GZT9 1/20 0.33
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5706486 0.84 MEN1 (0.44) KMT2AMEN1RAB9AGAASMN1; SMN2
SCHEMBL352333 0.79 RAB9A (0.41) KMT2AMEN1RAB9ASMN1; SMN2NPC1
SCHEMBL353219 0.71 PRKCI (0.35) KMT2AMEN1RAB9AGAASMN1; SMN2
SCHEMBL351794 0.69 PARK7 (0.51) KMT2AMEN1GAANPC1KDM4E
SCHEMBL31185958 0.64 KDM4E (0.57) KMT2AMEN1RAB9AKDM4EALDH1A1
SCHEMBL107721 0.64 KDM4E (0.57) KMT2AMEN1RAB9AKDM4EALDH1A1
SCHEMBL93650 0.64 GAA (0.48) KMT2AMEN1GAASMN1; SMN2TP53
SCHEMBL26336039 0.63 MAPK8 (0.48) KMT2ASMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL354123 0.63 BRD4 (0.44) KMT2AMEN1RAB9AGAASMN1; SMN2
SCHEMBL5706505 0.63 NPC1 (0.44) KMT2AMEN1RAB9AGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
EP-2411376-A1 INHIBITORS OF NF-KB Profectus Biosciences, Inc. (US) 2012-02-01 EP disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed
WO-2010111460-A1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG KMT2A 2968/4885MEN1 2854/4885RAB9A 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.